A competition class action against Stanwell and CS Energy has been tossed, with a judge finding the power companies’ conduct was legitimate âprofit maximisation behaviourâ.Â
Nuix had information in January 2021 which undermined the growth story presented to the market in the prospectus for its IPO, a court has heard on the first day of ASICâs case against the tech company and a handful of former directors.
As it readies its civil penalty suit against tech company Nuix for trial, ASIC has flagged a possible dispute about the extent of penalty privilege pleaded by a handful of former and current directors named in the case.
Telstra and TPG will not challenge a decision by the Australian Competition Tribunal to uphold the ACCC’s rejection of their proposed regional network sharing agreement.
Telstra and TPG have lost their challenge to the ACCCâs decision refusing authorisation for a $1.8 billion regional network sharing agreement, with the Australian Competition Tribunal finding the deal would increase Telstra’s dominance in the mobile phone market.Â
Telstra and TPG have asked the Competition Tribunal to undo the ACCC’s rejection of their proposed regional network sharing agreement, but fellow telco Optus has warned the deal would kneecap its ability to compete.
The ACCC’s rejection of a regional network arrangement between Telstra and TPG was “confusing” and the telecos might be free to vary the transaction, says a judge who is overseeing a challenge to the competition regulator’s decision.
Bristol-Myers Squibb has agreed to open up its subsidised treatment program for stage IV melanoma patients to individuals who have been treated with drugs made by its competitors to settle a misuse of market power lawsuit brought by rival Merck Sharpe & Dohme.
The Port of Newcastle has largely won its High Court fight with mining giant Glencore over access fees and will now be able to set a higher price for use of the port’s facilities.
Pharmaceutical giant Bristol-Myers Squibb will fight a case brought by Merck Sharp & Dohme alleging misuse of market power over stage IV melanoma treatments, telling the Federal Court on Friday it denied its rival’s claims.